{"id":3555,"date":"2022-09-05T19:35:44","date_gmt":"2022-09-05T19:35:44","guid":{"rendered":"https:\/\/palynziqhcp-dev-001.azurewebsites.net\/en-us\/palynziq\/?page_id=3555"},"modified":"2024-06-12T13:39:54","modified_gmt":"2024-06-12T13:39:54","slug":"mechanism-of-action-and-efficacy-video","status":"publish","type":"page","link":"https:\/\/hcp.biomarin.com\/en-us\/palynziq\/mechanism-of-action-and-efficacy-video\/","title":{"rendered":"Mechanism of Action and Efficacy – Video"},"content":{"rendered":"
For Healthcare Professionals<\/small><\/p>\n
Mechanism of Action and Efficacy<\/strong><\/p>\n Dr. Barbara Burton and Heather Bausell, RD, LDN, from Ann & Robert H. Lurie Children\u2019s Hospital of Chicago discuss PALYNZIQ\u2019s mechanism of action and efficacy data associated with significant blood Phe reduction to reach meaningful blood Phe targets.<\/p>\n Indication<\/strong><\/p>\n PALYNZIQ is a phenylalanine (Phe)-metabolizing enzyme indicated to reduce blood Phe concentrations in adult patients with phenylketonuria who have uncontrolled blood Phe concentrations greater than 600 micromol\/L on existing management.
\n
\nPlease see full Prescribing Information<\/a>, with Boxed Warning for risk of anaphylaxis, and Medication Guide, here<\/a>.<\/strong><\/p>\n